Top Markets
#1 ONFA ONFA +213.40%
#2 Noon Noon +41.33%
#3 Doge Strategy Doge Strategy +38.28%
#4 StakeStone StakeStone +36.72%
#5 BLOCKv BLOCKv +17.41%
#6 Orochi Network Orochi Network +16.42%
#7 Trusta AI Trusta AI +15.16%
#8 PlaysOut PlaysOut +14.18%
#9 PUMPCADE PUMPCADE +13.67%
#10 TronBank TronBank +12.39%
Coin of the day
ONFA ONFA
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Johnson & Johnson Johnson & Johnson

Johnson & Johnson

JNJ
Kedudukan dalam Saham #18
Johnson & Johnson, together with its subsidiaries, researches and develops,... Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Harga Saham
$240.45
Modal Pasaran
$579.46B
Perubahan (1 hari)
0.51%
Perubahan (1 tahun)
46.88%
Negara
US
Perdagangan Johnson & Johnson (JNJ)

Kategori

Healthcare
Nisbah P/E bagi Johnson & Johnson (JNJ)
Nisbah P/E pada March 2026 TTM: 21.88
Menurut laporan kewangan dan harga saham terkini Johnson & Johnson, nisbah P/E semasa (TTM) ialah 21.88. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 24.53.
Sejarah nisbah P/E bagi Johnson & Johnson dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 21.88 16.71%
2025 18.75 -23.56%
2024 24.53 117.16%
2023 11.30 -47.70%
2022 21.60 -22.85%
2021 28.00 10.67%
2019 25.30 12.64%
2018 22.46 -92.21%
2017 288.31 1,504.75%
2016 17.97 0.04%
2014 17.96 -4.59%
2013 18.82 4.89%
2012 17.95 39.12%
2011 12.90 -11.36%
2010 14.55 15.26%
2008 12.63 -30.55%
2007 18.18 3.55%
2006 17.56 -23.07%
2005 22.82 7.99%
2003 21.14 -13.54%
2002 24.45 -22.65%
2001 31.60 -0.45%
2000 31.75 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 42.86 95.87%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 92.55 322.93%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 20.85 -4.72%
CH
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 28.47 30.08%
GB
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 15.77 -27.93%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.